Finance

Lists
Why is 214390 up 2.29%?
Dive Deeper
214390:KRX
Kyongbo Pharmaceutical Co Ltd
₩5,370.00
+2.29%
(+120.00) 1D
Oct 19, 2:03:02 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 214390...
Open
₩5,250
High
₩5,400
Low
₩5,250
Mkt. cap
128.38B
Avg. vol.
24.96K
Volume
11.10K
Dividend
0.93%
Quarterly dividend
₩13
Ex-dividend date
Dec 29, 2025
P/E ratio
25.50
52-wk high
₩9,300
52-wk low
₩4,700
EPS
₩211
Shares outstanding
23.91M
No. of employees
588
Open
₩5,250
High
₩5,400
Low
₩5,250
Mkt. cap
128.38B
Avg. vol.
24.96K
Volume
11.10K
Dividend
0.93%
Quarterly dividend
₩13
Ex-dividend date
Dec 29, 2025
P/E ratio
25.50
52-wk high
₩9,300
52-wk low
₩4,700
EPS
₩211
Shares outstanding
23.91M
No. of employees
588
News stories
From web sources and news partners
About Kyongbo Pharmaceutical Co Ltd
CEOKim Tae-young
Employees588
FoundedMar 31, 1987
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in KRW
Loading Previous Earnings...
Revenue
Net income
All values in KRW
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
66.99B
71.22B
66.13B
75.22B
Cost of goods sold
42.39B
44.46B
38.69B
46.54B
Cost of revenue
42.39B
44.46B
38.69B
46.54B
Research and development expenses
4.46B
4.50B
4.92B
4.99B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
18.88B
20.67B
20.97B
21.99B
Operating expense
24.12B
26.24B
26.73B
27.75B
Total operating expenses
66.51B
70.70B
65.41B
74.29B
Operating income
474.48M
515.50M
712.77M
930.33M
Other non operating income
-1.10B
2.51B
-1.44B
3.36B
EBT including unusual items
3.44B
-995.05M
-741.91M
4.27B
EBT excluding unusual items
3.44B
-857.95M
-741.91M
4.27B
Income tax expense
412.26M
-562.40M
-212.24M
1.29B
Effective tax rate
11.97%
56.52%
28.61%
30.33%
Other operating expenses
194.62M
276.72M
190.08M
187.64M
Net income
3.03B
-432.65M
-529.67M
2.97B
Net profit margin
4.53%
-0.61%
-0.80%
3.95%
Earnings per share
-
-
-
-
Interest and investment income
-
41.30M
-
-
Interest expense
-
-4.29B
-
-
Net interest expenses
-
-4.25B
-
-
Depreciation and amortization charges
377.69M
385.22M
323.46M
327.67M
EBITDA
3.86B
3.95B
4.29B
4.64B
Gain or loss from assets sale
-6.40M
10.00K
-5.48M
13.90M
AI content may include mistakes. Learn more
Google apps